Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Shares Outstanding (Diluted Average): 2021-2025

Historic Shares Outstanding (Diluted Average) for SAB Biotherapeutics (SABS) over the last 4 years, with Sep 2025 value amounting to $77.9 million.

  • SAB Biotherapeutics' Shares Outstanding (Diluted Average) rose 740.93% to $77.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 740.93%. This contributed to the annual value of $9.3 million for FY2024, which is 67.74% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $77.9 million for Q3 2025, which was up 737.74% from $9.3 million recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $77.9 million for Q3 2025, and its period low was $4.4 million during Q4 2022.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $14.0 million, with a median of $9.3 million in 2024.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first plummeted by 88.29% in 2023, then soared by 740.93% in 2025.
  • Over the past 5 years, SAB Biotherapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $26.0 million in 2021, then spiked by 65.72% to $4.4 million in 2022, then grew by 26.86% to $5.5 million in 2023, then soared by 67.74% to $9.3 million in 2024, then surged by 740.93% to $77.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $77.9 million for Q3 2025, versus $9.3 million for Q2 2025 and $9.3 million for Q1 2025.